Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Able to be dosed in both eyes, able and willing to make the required study visits and to follow instructions.~* Negative urine pregnancy test if female of childbearing potential and use adequate birth control throughout the study period.~* Diagnostic skin test indicative of allergy for cat hair, cat dander, grasses, ragweed, dust mite, dog dander, cockroach and/or trees within 24 months prior to Visit 1 or at Visit 1.~* History of seasonal or perennial allergic conjunctivitis for at least 1 year prior to Visit 1.~* Best-corrected visual acuity of 55 or greater in each eye as measured by ETDRS (letters read method).~* Manifest a positive bilateral Conjunctival Allergen Challenge (CAC) test response.~* Willing to discontinue contact lens wear for at least 72 hours prior to Visit 1 and throughout the study.~* Other protocol-defined inclusion criteria may apply.~Exclusion Criteria:~* Known history or presence of persistent dry eye syndrome, or currently requires frequent use of artificial tears, gels or lubricants, presence of punctal plugs, use of Restasis®, or topical ocular corticosteroids for dryness of eyes.~* Presence of an ocular condition that may affect the study outcomes.~* History or evidence of ocular surgery (including refractive procedures such as LASIK, PRK and RK) within 6 months of Visit 1.~* Presence of signs/symptoms of active allergic conjunctivitis at the start of Visits 1, 2, 3A, or 4.~* History of anaphylactic reaction to any allergens used in this study.~* Current evidence or recent (within 6 months) history of severe, unstable, or uncontrolled medical conditions and/or other relevant systemic diseases.~* Use of any disallowed medication without protocol-specified washout period prior to Visit 1, or during the study.~* Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AL-4943A (Type: EXPERIMENTAL): AL-4943A ophthalmic solution, 1 drop per eye Day 0, followed by 1 drop per eye Day 14
- PATADAY (Type: ACTIVE_COMPARATOR): Olopatadine hydrochloride ophthalmic solution, 0.2%, 1 drop per eye Day 0, followed by 1 drop per eye Day 14
- PATANOL (Type: ACTIVE_COMPARATOR): Olopatadine hydrochloride ophthalmic solution, 0.1%, 1 drop per eye Day 0, followed by 1 drop per eye Day 14
- Vehicle (Type: PLACEBO_COMPARATOR): AL-4943A ophthalmic solution vehicle, 1 drop per eye Day 0, followed by 1 drop per eye Day 14

Based on this trial design, predict the completion outcome and termination type (if applicable).